VERA Filings — Vera Therapeutics, Inc. - FilingSpy
VERA
Vera Therapeutics, Inc.
A biotechnology company developing treatments for autoimmune and kidney diseases, Vera Therapeutics makes Trutakna (atacicept), a self-administered injectable for adults with IgA nephropathy, a kidney condition driven by the immune system. It began in 2016 as Trucode Gene Repair before rebranding to Vera — Latin for "truth," echoing its motto "truth in science" — and pivoting to immunology and kidney disease. Its lead drug won U.S. approval in 2026 as a first-in-class therapy for the condition.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -2.05M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.